SCHEMBL4803335

SCHEMBL4803335

CCOC(=O)C(CC)CN(C(=O)OCC)C(C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
KMT2A Q03164 1/20 0.34
EPHX2 P34913 4/20 0.34
PPARG P37231 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 1/20 0.32
SOAT1 P35610 1/20 0.31
PPARA Q07869 1/20 0.31
CA2 P00918 1/20 0.31
MAPK1 P28482 1/20 0.31
CPB2 Q96IY4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4803342 1.00 L3MBTL1 (0.40) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4804601 0.91 EPHX2 (0.35) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4804598 0.91 EPHX2 (0.35) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4612254 0.87 TDP1 (0.34) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4805760 0.87 NFKB1 (0.33) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4805755 0.87 NFKB1 (0.33) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4796480 0.84 ALDH1A1 (0.49) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL20165470 0.83 ALDH1A1 (0.44) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL20165513 0.79 ALDH1A1 (0.46) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL31346620 0.77 ALDH1A1 (0.42) L3MBTL1ALDH1A1LMNAPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980096-A Process for synthesizing ton-grade perindopril tert-butylamine 绍兴市上虞区武汉理工大学高等研究院 2022-01-28 CN disclosed
US-7326794-B2 Process for the preparation of high purity perindopril and intermediates useful in the synthesis LES LABORATOIRES SERVIER (FR) 2008-02-05 US disclosed
US-7279595-B2 Process for the preparation of high purity perindopril LES LABORATOIRES SERVIER (FR) 2007-10-09 US disclosed
US-20070197821-A1 Process for the preparation of high purity perindopril LES LABORATOIRES SERVIER (FR) 2007-08-23 US disclosed
EP-1333026-B1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis SERVIER LAB (FR) 2007-06-27 EP disclosed
US-20050119492-A1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis LES LABORATOIRES SERVIER (FR) 2005-06-02 US disclosed
WO-2003064388-A2 PROCESS FOR THE PREPARATION OF HIGH PURITY PERINDOPRIL AND INTERMEDIATES USEFUL IN THE SYNTHESIS LES LABORATOIRES SERVIER (FR) 2003-08-07 WO disclosed
EP-1333026-A1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis Les Laboratoires Servier (FR) 2003-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197821-A1 Process for the preparation of high purity perindopril ACE, AGTR1, ACE2 L3MBTL1 3991/4885ALDH1A1 142/4885LMNA 1116/4885
US-20050119492-A1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis ACE, AGTR1, ACE2 L3MBTL1 3953/4885ALDH1A1 150/4885LMNA 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.